Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix
OBJECTIVES: I. Determine the safety and efficacy of bryostatin-1 plus cisplatin in patients
with recurrent or advanced carcinoma of the cervix. II. Determine the response rate,
progression free interval, and duration of survival of these patients when treated with this
regimen.
OUTLINE: This is a multicenter study. Patients receive bryostatin-1 IV over 1 hour and
cisplatin IV over 1 hour on day 1. Treatment continues every 21 days in the absence of
disease progression or unacceptable toxicity. Patients are followed until death.
PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study over 2-3 years.
Interventional
Primary Purpose: Treatment
Farr R. Nezhat, MD
Study Chair
Mount Sinai School of Medicine
United States: Federal Government
CDR0000067948
NCT00005965
August 2000
Name | Location |
---|---|
Albert Einstein Comprehensive Cancer Center | Bronx, New York 10461 |
Mount Sinai Medical Center, NY | New York, New York 10029 |
New York Presbyterian Hospital - Cornell Campus | New York, New York 10021 |
NYU School of Medicine's Kaplan Comprehensive Cancer Center | New York, New York 10016 |
New York Medical College | Valhalla, New York 10595 |
Saint Vincent Catholic Medical Center of New York | New York, New York 10011 |